Gains in life expectancy from medical interventions - Standardizing data on outcomes

New England Journal of Medicine

Volumn 339, Issue 6, 1998, Pages 380-386

  Wright, Janice C ^a   Weinstein, Milton C ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; LIFE EXPECTANCY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; INFANT, NEWBORN; LIFE EXPECTANCY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREVENTIVE MEDICINE; RISK FACTORS; SURVIVAL ANALYSIS; THERAPEUTICS;

EID: 0032491032     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808063390606     Document Type: Article

References (37)

1. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113: 373-84.
2. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318: 1728-33.
3. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 1994;9:702-7.
4. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996;124:577-84.
5. Kassirer JP, Moskowitz AJ, Lau J, Pauker SG. Decision analysis: a progress report. Ann Intern Med 1987;106:275-91.
6. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-41.
8. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health 1988;78:1417-21. [Erratum, Am J Public Health 1989;79: 273.]
9. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991;83:1194-201. [Erratum, Circulation 1991;84:2610.)
10. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-37.
11. Lindfors KK, Rosenquist J. The cost-effectiveness of mammographic screening strategies. JAMA 1995;274:881-4. [Erratum JAMA 1996;275: 112.]
12. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113: 214-26.
13. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985;75: 739-44.
14. Hinman AR, Koplan JP. Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. JAMA 1984;251:3109-13.
15. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-306.
16. Feldman S, Berkowitz RS, Tosteson ANA. Cost effectiveness of strategies to evaluate postmenopausal bleeding. Obstet Gynecol 1993;81:968-75.
17. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71. [Erratum, N Engl J Med 1997;337:434.]
18. Carson JL, Russell LB, Taragin MI, Sonnenberg FA, Duff AE, Bauer S. The risks of blood transfusion: the relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis. Am J Med 1992;92:45-52.
19. Birkmeyer JD, AuBuchon JP, Littenburg B, et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg 1994;57:161-8.
20. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113:852-71.
21. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.
22. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis - a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J 1992;13:2-8.
23. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24. [Erratum, N Engl J Med 1995;333:267.]
24. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992;19:1323-34.
25. O'Brien BJ, Buxton MJ, Ferguson BA. Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis. J Chronic Dis 1987;40:Suppl 1:137S-158S.
26. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994;25:1149-56.
27. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
28. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-8.
29. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51:111-6. [Erratum, Eur J Clin Pharmacol 1997;51:427.]
30. Goodwin PJ, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988;6:1537-47.
31. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8:1301-9.
32. Shibley L, Brown M, Schuttinga J, Rothenberg M, Whalen J. Cisplatin-based combination chemotherapy in the treatment of advanced-stage testicular cancer: cost-benefit analysis. J Natl Cancer Inst 1990;82:186-92.
33. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:275-81.
34. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.
35. Ransohoff DF, Gracie WA. Treatment of gallstones. Ann Intern Med 1993;119:606-19.
36. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
37. Neutra R. Indications for the surgical treatment of suspected acute appendicitis: a cost-effectiveness approach. In: Bunker JP, Barnes BA, Mosteller F, eds. Costs, risks, and benefits of surgery. New York: Oxford University Press, 1977:277-307.